Impact of Durvalumab as Consolidation Therapy in NSCLC

Julie R. Brahmer, MD

Julie R. Brahmer, MD, associate professor of oncology and co-director of the Upper Aerodigestive Department at the Bloomberg Kimmel Institute for Cancer Immunotherapy, John Hopkins Medicine, discusses the change in standard of care for patients with stage III non–small cell lung cancer. Durvalumab was recently approved by the FDA as a consolidation therapy for patients with stage III locally-advanced, unresectable NSCLC who had not progressed following standard chemoradiotherapy.

Julie R. Brahmer, MD, associate professor of oncology and co-director of the Upper Aerodigestive Department at the Bloomberg Kimmel Institute for Cancer Immunotherapy, John Hopkins Medicine, discusses the change in standard of care for patients with stage III non—small cell lung cancer (NSCLC). Durvalumab (Imfinzi) was recently approved by the FDA as a consolidation therapy for patients with stage III locally-advanced, unresectable NSCLC who had not progressed following standard chemoradiotherapy.